Quantum BioPharma Posts Q2 2026 Loss of $3.1M; GBB Trial Set for Aug 24
QNTM sits 57% above its 52-week low of $2.07.
Summary
Quantum BioPharma reported a narrower Q2 2026 net loss of $3.1 million and disclosed that its GBB trade secrets lawsuit will go to trial on August 24, 2026.
Key Events · Earnings and Guidance · QNTM
-
Q2 Net Loss Narrows to $3.1M
Net loss for Q2 2026 was $3.09 million, down from $9.77 million in Q2 2025, driven by a 47% reduction in operating expenses and lower non-cash warrant liability charges.
-
Cash Position at $3.65M
Cash and cash equivalents totaled $3.65 million as of June 30, 2026, after raising $8.1 million in gross proceeds from the ATM offering and $2.73 million from March 2026 convertible debentures during the first half.
-
GBB Trial Set for August 24
The GBB Drink Lab litigation, alleging trade secret misappropriation with claimed asset value of $53 million, is scheduled for a two-week trial starting August 24, 2026, after a failed settlement conference on August 7.
-
Heavy Dilution from Convertible Financing
The March 2026 debentures have a conversion price of C$3.00 per share, significantly below the current stock price, and 794,176 shares were already issued upon conversion during H1 2026, with more conversions occurring after quarter-end.
Analysis · QNTM · Life Sciences
Quantum BioPharma's Q2 2026 results show a net loss of $3.09 million, an improvement from $9.77 million a year earlier, driven by lower operating expenses and a smaller non-cash warrant liability charge. The company ended the quarter with $3.65 million in cash after raising $8.1 million through its at-the-market offering and $2.73 million from convertible debentures. The GBB litigation, which alleges trade secret misappropriation and seeks damages based on a $53 million asset valuation, is now set for trial on August 24, 2026, creating a near-term binary risk for the company.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1625 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNTM was trading at $3.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.7M. The 52-week trading range was $2.07 to $25.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.